Clinical Trials Logo

Clinical Trial Summary

a multicenter, double-blind, randomized, placebo-controlled trial. Patients aged less than 60 years old with no previous medical history consulting the emergency department for covid and covid-like illness and who were not hospitalized were included. Those who have known allergy or severe side effect on the study drugs and those who refused to consent were excluded. Pregnant women were not included. For all the included patients, a PCR test for the detection of SARS COV2 was realized. Patients were assigned in a 1:1 ratio to the treatment group or the placebo group. The treatment group received two pills in the morning containing Vit C Vit D zinc and minerals and one pill of 2 mg of melatonin in the evening . Patients from the placebo group received three similar pills . The pills were identical in color, taste, smell, consistency, and container


Clinical Trial Description

This was a multicenter, double-blind, randomized, placebo-controlled trial. The study was approved by the ethics committee of the the Faculty of Medicine "Ibn El Jazzar" of Sousse. Patients provided written informed consent before participation. Patients were recruited from Sahloul emergency department, F.Hached emergency department, F.Bourguiba emergency department. Patients aged less than 60 years old with no previous medical history consulting the emergency department for covid and covid-like illness and who were not hospitalized were included. Those who have known allergy or severe side effect on the study drugs and those who refused to consent were excluded. Pregnant women were not included. For all the included patients, a PCR test for the detection of SARS COV2 was realized. Patients were assigned in a 1:1 ratio to the treatment group or the placebo group. The randomization list was created using a computer-generated code. A staff member who had no role in the study managed the randomization. The treatment group received two pills in the morning containing Vit C Vit D zinc and minerals and one pill of 2 mg of melatonin in the evening . Patients from the placebo group received three similar pills . The pills were identical in color, taste, smell, consistency, and container. They were prepared by XEn Plus laboratory members and labeled by a staff member who did not participate in the study. Patients and investigators remained blinded to randomization until the final analysis. After consenting, patients were examined by an emergency resident. They were asked about the common Covid-19 and Covid-like illness signs: fever, headache, asthenia/fatigue, sputum expectoration, anosmia, chills, skin rash, diarrhea, sore throat, abdominal pain, cough, vomiting, chest pain, hemoptysis, joint pain, ageusia, dyspnea, muscle pain and conjunctives. On physical examination vital signs were checked: blood pressure, pulse rate, respiration rate, body temperature, glycemic index, oxygen saturation and height and weight. This symptoms were assessed using a scale from 0 to 3 (not at all, slight, a lot, awful) and they were monitored via telecommunication. A follow-up was carried for each included patient on day 1, day 10, day 15 and day 30. Compliance with treatment, the date of disappearance of symptoms, side effects, adverse events, hospitalization, respiratory assistance requirement and death were mentioned accordingly ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05670444
Study type Interventional
Source Hôpital Universitaire Sahloul
Contact
Status Completed
Phase Phase 1
Start date January 2, 2023
Completion date February 28, 2023

See also
  Status Clinical Trial Phase
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Not yet recruiting NCT04525118 - Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-based Study Platform
Completed NCT04043923 - Norketotifen for the Treatment of Uncomplicated Influenza-like Illness Phase 2
Enrolling by invitation NCT05084898 - Far-UVC Light Devices in Long-term Care Facilities to Reduce Infections N/A
Recruiting NCT05036941 - A Trial of Two Mask Systems in Preventing SARS CoV-2 in Healthcare Workers (HCW) N/A
Recruiting NCT05050825 - Validation of a CDSA Strategy to Reduce Antibiotic Prescription in Senegal N/A
Active, not recruiting NCT03965195 - Recombinant Influenza Vaccination in U.S. Nursing Homes Phase 4
Recruiting NCT05704335 - InfluenCEF Study: Study on the Headache Associated With Influenza Infection
Completed NCT04610047 - Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness Phase 2
Completed NCT04245800 - Home Testing of Respiratory Illness
Active, not recruiting NCT05012189 - Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks Phase 4
Not yet recruiting NCT04716543 - Epidemiological Investigation of COVID-19 in Laos Using a One-Health Approach in Human and Animals
Completed NCT04320862 - COVID-19 Pandemic Response Network